16 Jan 2024 07:30
RNS Number : 7148Z
Official List
16 January 2024
NOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST |
16/01/2024 07:30 |
TEMPORARY SUSPENSION |
Dechra Pharmaceuticals PLC |
The Financial Conduct Authority ("the FCA") temporarily suspends the securities set out below from the Official List effective from 16/01/2024 07:30 at the request of the company: |
Security Description | Listing Category | ISIN | Ordinary Shares of 1p each; fully paid | Premium Equity Commercial Companies | GB0009633180 ? |
This notice has been issued by Issuer Management - 020 7066 8352. NotesSEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange identifier may be found on their dealing notice.?Denotes the security is being admitted to trading on the London Stock Exchange, a Recognised Investment Exchange.?Denotes the security is also being admitted to trading on Aquis Stock Exchange, a Recognised Investment Exchange.#Denotes the security is also being admitted to trading on Euronext, a Recognised Investment Exchange. ?Denotes the security is also being admitted to trading on Cboe Europe, a Recognised Investment Exchange.^Denotes the security is also being admitted to trading on Shanghai-London Stock Connect, a Recognised Investment Exchange.*Denotes the security is also being admitted to trading on IPSX Prime, a Recognised Investment Exchange.Notices issued by the FCA in respect of admission of securities to the Official List must be read in conjunction with notices issued by the relevant Recognised Investment Exchange in respect of admission of securities to trading on its markets. |
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
SUSSFUFFIELSESF
